Sagimet Biosciences Inc. NGM · SGMT

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

GlobeNewswire Inc. · 19d ago

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. · 25d ago

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

GlobeNewswire Inc. · 89d ago

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. · 103d ago

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire Inc. · 163d ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

GlobeNewswire Inc. · 267d ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

GlobeNewswire Inc. · 304d ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

GlobeNewswire Inc. · 311d ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

GlobeNewswire Inc. · 347d ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

GlobeNewswire Inc. · 404d ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. · 655d ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

GlobeNewswire Inc. · 772d ago

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday

Benzinga · 793d ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

GlobeNewswire Inc. · 793d ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

GlobeNewswire Inc. · 803d ago

Wall Street Breakfast: The Week Ahead

Seeking Alpha · 811d ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

GlobeNewswire Inc. · 843d ago

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga · 845d ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

GlobeNewswire Inc. · 845d ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire Inc. · 845d ago

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

The Motley Fool · 853d ago

Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga · 893d ago

KLA Reports Q2 Results, Joins Visa, Western Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Benzinga · 904d ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

GlobeNewswire Inc. · 904d ago

Texas Instruments Reports Q4 Results, Joins BlackBerry And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Benzinga · 906d ago